688606 奥泰生物
已收盘 01-13 15:00:01
资讯
新帖
简况
奥泰生物（688606）披露2024年限制性股票激励计划首次授予第一个归属期归属结果，12月12日股价上涨1.81%
证券之星 · 2025-12-12
奥泰生物（688606）披露2024年限制性股票激励计划首次授予第一个归属期归属结果，12月12日股价上涨1.81%
奥泰生物（688606）披露取消监事会并修订公司章程议案获通过，11月25日股价上涨0.95%
证券之星 · 2025-11-25
奥泰生物（688606）披露取消监事会并修订公司章程议案获通过，11月25日股价上涨0.95%
每周股票复盘：奥泰生物（688606）拟取消监事会
证券之星 · 2025-11-16
每周股票复盘：奥泰生物（688606）拟取消监事会
奥泰生物（688606）披露拟取消监事会并修订公司章程，11月13日股价上涨0.51%
证券之星 · 2025-11-13
奥泰生物（688606）披露拟取消监事会并修订公司章程，11月13日股价上涨0.51%
奥泰生物、奥浦迈生物、恒瑞医药高管同台探讨：中国何时诞生世界级医药企业？
新浪证券 · 2025-11-13
奥泰生物、奥浦迈生物、恒瑞医药高管同台探讨：中国何时诞生世界级医药企业？
奥泰生物高飞：AI能否真正提升药物筛选和研发效率，还需要时间和实践去检验
新浪证券 · 2025-11-13
奥泰生物高飞：AI能否真正提升药物筛选和研发效率，还需要时间和实践去检验
每周股票复盘：奥泰生物（688606）Q3净利降21.52%
证券之星 · 2025-11-02
每周股票复盘：奥泰生物（688606）Q3净利降21.52%
奥泰生物（688606）披露2025年第三季度报告，10月31日股价上涨0.85%
证券之星 · 2025-10-31
奥泰生物（688606）披露2025年第三季度报告，10月31日股价上涨0.85%
图解奥泰生物三季报：第三季度单季净利润同比下降21.52%
证券之星 · 2025-10-30
图解奥泰生物三季报：第三季度单季净利润同比下降21.52%
每周股票复盘：奥泰生物（688606）每股派现1.0000元（含税）
证券之星 · 2025-10-12
每周股票复盘：奥泰生物（688606）每股派现1.0000元（含税）
每周股票复盘：奥泰生物（688606）中期拟每10股派10元
证券之星 · 2025-09-21
每周股票复盘：奥泰生物（688606）中期拟每10股派10元
奥泰生物（688606）披露2025年中期利润分配方案，9月18日股价下跌1.45%
证券之星 · 2025-09-18
奥泰生物（688606）披露2025年中期利润分配方案，9月18日股价下跌1.45%
奥泰生物(688606.SH)2025年中期利润分配拟10股派10元
智通财经 · 2025-09-18
奥泰生物(688606.SH)2025年中期利润分配拟10股派10元
每周股票复盘：奥泰生物（688606）股东户数增8.08%，中报营收增8.41%
证券之星 · 2025-08-31
每周股票复盘：奥泰生物（688606）股东户数增8.08%，中报营收增8.41%
奥泰生物（688606）2025年中报简析：营收净利润同比双双增长，三费占比上升明显
证券之星 · 2025-08-31
奥泰生物（688606）2025年中报简析：营收净利润同比双双增长，三费占比上升明显
图解奥泰生物中报：第二季度单季净利润同比下降10.49%
证券之星 · 2025-08-29
图解奥泰生物中报：第二季度单季净利润同比下降10.49%
医疗器械行业行业研究：脑机接口行业深度：政策+创新双轮驱动，商业化落地进入快车道
国金证券 · 2025-08-10
医疗器械行业行业研究：脑机接口行业深度：政策+创新双轮驱动，商业化落地进入快车道
每周股票复盘：奥泰生物（688606）调整限制性股票授予价格并确定归属名单
证券之星 · 2025-08-10
每周股票复盘：奥泰生物（688606）调整限制性股票授予价格并确定归属名单
奥泰生物：44万股限制性股票符合归属条件
财中社 · 2025-08-08
奥泰生物：44万股限制性股票符合归属条件
奥泰生物：8月8日召开董事会会议
每日经济新闻 · 2025-08-08
奥泰生物：8月8日召开董事会会议
加载更多
公司概况
公司名称：
杭州奥泰生物技术股份有限公司
所属行业：
医药制造业
上市日期：
2021-03-25
主营业务：
杭州奥泰生物技术股份有限公司的主营业务是体外快速诊断试剂的研发、生产和销售。公司的主要产品是传染病类、毒品及药物滥用类、妇女健康类、新冠检测类、肿瘤类、心肌类。报告期内，公司新增授权专利/软件著作权共23项；新增国内外医疗器械产品认证203项。截至报告期末，公司已累计获得专利/软件著作权219项，累计已取得国内外医疗器械备案以及产品注册证书3058项。
发行价格：
133.67
{"stockData":{"symbol":"688606","market":"SH","secType":"STK","nameCN":"奥泰生物","latestPrice":65.97,"timestamp":1768287601000,"preClose":65.7,"halted":0,"volume":634341,"delay":0,"changeRate":0.0041,"floatShares":79280900,"shares":79280900,"eps":3.7179,"marketStatus":"已收盘","change":0.27,"latestTime":"01-13 15:00:01","open":65.65,"high":66.85,"low":65.65,"amount":42078800,"amplitude":0.0183,"askPrice":65.97,"askSize":1,"bidPrice":65.94,"bidSize":6,"shortable":0,"etf":0,"ttmEps":3.7179,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768354200000},"marketStatusCode":5,"adr":0,"adjPreClose":65.7,"symbolType":"stock_kcb","openAndCloseTimeList":[[1768267800000,1768275000000],[1768280400000,1768287600000]],"highLimit":72.27,"lowLimit":59.13,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":79280855,"isCdr":false,"pbRate":1.34,"roa":"--","peRate":17.743888,"roe":"4.85%","epsLYR":3.82,"committee":-0.525641,"marketValue":5230000000,"turnoverRate":0.008,"status":0,"afterMarket":{"amount":0,"volume":0,"close":65.97,"buyVolume":0,"sellVolume":0,"time":1768289637558,"indexStatus":"已收盘 01-13 15:30:00","preClose":65.7},"floatMarketCap":5230000000},"requestUrl":"/m/hq/s/688606","defaultTab":"news","newsList":[{"id":"2590502609","title":"奥泰生物（688606）披露2024年限制性股票激励计划首次授予第一个归属期归属结果，12月12日股价上涨1.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590502609","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590502609?lang=zh_cn&edition=full","pubTime":"2025-12-12 22:31","pubTimestamp":1765549872,"startTime":"0","endTime":"0","summary":"截至2025年12月12日收盘，奥泰生物报收于62.93元，较前一交易日上涨1.81%，最新总市值为49.89亿元。近日，奥泰生物发布关于2024年限制性股票激励计划首次授予第一个归属期归属结果的公告。公告显示，公司已完成2024年限制性股票激励计划首次授予第一个归属期的股份登记，本次归属股票数量为381,100股，来源为公司从二级市场回购的A股普通股股票，归属人数为54人。经审验，公司已收到激励对象认缴股款9,646,250.76元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121200042029.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688606"],"gpt_icon":0},{"id":"2586719664","title":"奥泰生物（688606）披露取消监事会并修订公司章程议案获通过，11月25日股价上涨0.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586719664","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586719664?lang=zh_cn&edition=full","pubTime":"2025-11-25 22:36","pubTimestamp":1764081362,"startTime":"0","endTime":"0","summary":"截至2025年11月25日收盘，奥泰生物报收于66.69元，较前一交易日上涨0.95%，最新总市值为52.87亿元。该股当日开盘65.82元，最高67.02元，最低65.82元，成交额达1369.42万元，换手率为0.26%。根据近日发布的公告，杭州奥泰生物技术股份有限公司于2025年11月25日召开2025年第二次临时股东大会，审议通过了《关于取消监事会、修订<公司章程>并办理工商变更登记的议案》。该议案为特别决议议案，获得出席股东所持表决权三分之二以上通过。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112500039772.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688606"],"gpt_icon":0},{"id":"2583548976","title":"每周股票复盘：奥泰生物（688606）拟取消监事会","url":"https://stock-news.laohu8.com/highlight/detail?id=2583548976","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583548976?lang=zh_cn&edition=full","pubTime":"2025-11-16 04:19","pubTimestamp":1763237949,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，奥泰生物报收于70.55元，较上周的67.96元上涨3.81%。本周，奥泰生物11月14日盘中最高价报71.45元。11月10日盘中最低价报67.7元。奥泰生物当前最新总市值55.93亿元，在医疗器械板块市值排名68/126，在两市A股市值排名3105/5165。同时，增选陈善基为第三届董事会独立董事。相关议案已提交第三届董事会第十七次会议审议通过，并提请2025年第二次临时股东大会审议。会议采取现场与网络投票相结合方式，于2025年11月25日召开。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600001190.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688606","BK0239"],"gpt_icon":0},{"id":"2583591818","title":"奥泰生物（688606）披露拟取消监事会并修订公司章程，11月13日股价上涨0.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583591818","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583591818?lang=zh_cn&edition=full","pubTime":"2025-11-13 22:50","pubTimestamp":1763045430,"startTime":"0","endTime":"0","summary":"截至2025年11月13日收盘，奥泰生物报收于70.45元，较前一交易日上涨0.51%，最新总市值为55.85亿元。该股当日开盘69.99元，最高70.68元，最低69.22元，成交额达3823.94万元，换手率为0.69%。近日，奥泰生物发布《2025年第二次临时股东大会会议资料》公告，宣布拟取消公司监事会，由董事会审计委员会行使监事会职权，并对《公司章程》及相关内部管理制度进行修订。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111300042764.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688606","BK0239"],"gpt_icon":0},{"id":"2583562646","title":"奥泰生物、奥浦迈生物、恒瑞医药高管同台探讨：中国何时诞生世界级医药企业？","url":"https://stock-news.laohu8.com/highlight/detail?id=2583562646","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583562646?lang=zh_cn&edition=full","pubTime":"2025-11-13 20:07","pubTimestamp":1763035620,"startTime":"0","endTime":"0","summary":" 11月13日，在上海证券交易所国际投资者大会的圆桌论坛上，嘉宾们围绕“中国能否诞生世界级的医药企业？” 杭州奥泰生物技术股份有限公司董事长、总经理高飞表示，世界级企业在中国“肯定会出现”。他表示，生物医药企业要在全球产生价值，必须先在中国市场形成价值基础，而国家在政策端的持续支持至关重要。 现场讨论认为，随着创新能力提升、政策不断完善，中国医药产业未来有望孕育世界级的一流企业。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-11-13/doc-infxhkcu5227361.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2289578879.USD","688606","LU1580142542.USD","BK0060","LU0405327494.USD","LU1997244956.HKD","LU1064130708.USD","LU1255011170.USD","688293","LU2580892789.USD","BK0196","LU1969619763.USD","LU2097828474.EUR","LU0359202008.SGD","LU2097828557.USD","BK0239","LU2097828805.USD","LU2488822045.USD","LU0405327148.USD","LU1781817850.SGD","LU1064131003.USD","LU1655091616.SGD","BK0028","LU1997245094.SGD","LU1820825898.SGD","LU1997245177.USD","LU2495084118.USD","LU1023057109.AUD","600276","BK0012","BK1191","LU0359201612.USD","LU1328615791.USD","LU2328871848.SGD","LU2097828631.EUR","LU2543165471.USD","BK0183","LU2580892862.HKD","LU0359201885.HKD","LU2148510915.USD","LU1146622755.USD","LU2097828714.EUR","BK0216","BK0188","01276"],"gpt_icon":0},{"id":"2583369345","title":"奥泰生物高飞：AI能否真正提升药物筛选和研发效率，还需要时间和实践去检验","url":"https://stock-news.laohu8.com/highlight/detail?id=2583369345","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583369345?lang=zh_cn&edition=full","pubTime":"2025-11-13 10:58","pubTimestamp":1763002680,"startTime":"0","endTime":"0","summary":" 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 高飞指出，医疗器械行业与创新药存在显著差异。 在谈及AI与医药行业的结合时，高飞表示，AI的热潮虽推动了创新药研发与医疗数据分析，但其在实际落地中仍需长期验证。“AI能否真正提升药物筛选和研发效率，还需要时间和实践去检验。”","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/marketresearch/2025-11-13/doc-infxfnye5570602.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","688606"],"gpt_icon":0},{"id":"2580405630","title":"每周股票复盘：奥泰生物（688606）Q3净利降21.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580405630","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580405630?lang=zh_cn&edition=full","pubTime":"2025-11-02 10:23","pubTimestamp":1762050189,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘，奥泰生物报收于68.8元，较上周的68.85元下跌0.07%。本周，奥泰生物10月28日盘中最高价报69.96元。奥泰生物当前最新总市值54.55亿元，在医疗器械板块市值排名65/126，在两市A股市值排名3085/5163。股本股东变化截至2025年9月30日，奥泰生物股东户数为5739户，较6月30日减少131户，减幅2.23%。业绩披露要点奥泰生物2025年三季报显示，前三季度主营收入6.33亿元，同比上升2.44%；归母净利润1.9亿元，同比下降3.91%；扣非净利润1.47亿元，同比下降4.7%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200002378.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688606","BK0239"],"gpt_icon":0},{"id":"2579505754","title":"奥泰生物（688606）披露2025年第三季度报告，10月31日股价上涨0.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579505754","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579505754?lang=zh_cn&edition=full","pubTime":"2025-10-31 18:32","pubTimestamp":1761906765,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘，奥泰生物报收于68.8元，较前一交易日上涨0.85%，最新总市值为54.55亿元。近日，奥泰生物发布《2025年第三季度报告》，披露了公司前三季度主要财务数据。截至2025年9月30日，公司总资产为4,242,026,338.42元，较上年度末增长1.34%；归属于上市公司股东的所有者权益为3,901,773,832.63元，较上年度末增长0.47%。公告指出，高飞与赵华芳通过一致行动协议合计控制公司52.76%的股份，为公司实际控制人。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100040055.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688606","BK0239"],"gpt_icon":0},{"id":"2579143659","title":"图解奥泰生物三季报：第三季度单季净利润同比下降21.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579143659","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579143659?lang=zh_cn&edition=full","pubTime":"2025-10-30 19:37","pubTimestamp":1761824262,"startTime":"0","endTime":"0","summary":"证券之星消息，奥泰生物2025年三季报显示，前三季度公司主营收入6.33亿元，同比上升2.44%；归母净利润1.9亿元，同比下降3.91%；扣非净利润1.47亿元，同比下降4.7%；其中2025年第三季度，公司单季度主营收入2.03亿元，同比下降8.26%；单季度归母净利润5779.7万元，同比下降21.52%；单季度扣非净利润3763.32万元，同比下降38.31%；负债率8.03%，投资收益883.17万元，财务费用-1237.33万元，毛利率56.21%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000040203.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688606"],"gpt_icon":0},{"id":"2574500534","title":"每周股票复盘：奥泰生物（688606）每股派现1.0000元（含税）","url":"https://stock-news.laohu8.com/highlight/detail?id=2574500534","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574500534?lang=zh_cn&edition=full","pubTime":"2025-10-12 02:58","pubTimestamp":1760209092,"startTime":"0","endTime":"0","summary":"截至2025年10月10日收盘，奥泰生物报收于68.39元，较上周的68.95元下跌0.81%。本周关注点公司公告汇总：奥泰生物每股派发现金红利1.0000元（含税），股权登记日为2025年10月15日。公司公告汇总杭州奥泰生物技术股份有限公司2025年半年度权益分派实施公告：本次利润分配以公司总股本79,280,855股为基数，扣除回购专用证券账户股份973,631股，实际参与分配股本为78,307,224股，每股派发现金红利1.0000元（含税），合计派发78,307,224.00元（含税），不送红股，不转增。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101200000753.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688606","BK0239"],"gpt_icon":0},{"id":"2569246485","title":"每周股票复盘：奥泰生物（688606）中期拟每10股派10元","url":"https://stock-news.laohu8.com/highlight/detail?id=2569246485","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569246485?lang=zh_cn&edition=full","pubTime":"2025-09-21 04:32","pubTimestamp":1758400331,"startTime":"0","endTime":"0","summary":"截至2025年9月19日收盘，奥泰生物报收于68.4元，较上周的68.2元上涨0.29%。本周，奥泰生物9月19日盘中最高价报68.47元。本周关注点公司公告汇总：奥泰生物2025年中期拟每10股派发现金红利10元（含税）。致同会计师事务所已于2025年8月19日对公司激励对象出资情况进行审验，确认收到认缴股款10,357,453.01元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092100001133.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688606","BK0239"],"gpt_icon":0},{"id":"2568406204","title":"奥泰生物（688606）披露2025年中期利润分配方案，9月18日股价下跌1.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2568406204","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568406204?lang=zh_cn&edition=full","pubTime":"2025-09-18 23:01","pubTimestamp":1758207681,"startTime":"0","endTime":"0","summary":"截至2025年9月18日收盘，奥泰生物报收于67.09元，较前一交易日下跌1.45%，最新总市值为53.19亿元。该股当日开盘68.2元，最高68.28元，最低66.7元，成交额达4978.25万元，换手率为0.93%。近日，奥泰生物发布2025年中期利润分配方案公告。截至公告披露日，公司总股本为79,280,855股，扣减回购股份973,631股后，参与分配股数为78,307,224股，拟派发现金红利78,307,224.00元（含税）。本次利润分配方案已由第三届董事会第十六次会议和第三届监事会第十六次会议审议通过，无需提交股东大会审议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091800037929.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688606"],"gpt_icon":0},{"id":"2568422489","title":"奥泰生物(688606.SH)2025年中期利润分配拟10股派10元","url":"https://stock-news.laohu8.com/highlight/detail?id=2568422489","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568422489?lang=zh_cn&edition=full","pubTime":"2025-09-18 16:24","pubTimestamp":1758183899,"startTime":"0","endTime":"0","summary":"智通财经APP讯，奥泰生物(688606.SH)公告，公司2025年中期利润分配方案拟每10股派发现金红利10元(含税)。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1346774.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688606"],"gpt_icon":0},{"id":"2563835947","title":"每周股票复盘：奥泰生物（688606）股东户数增8.08%，中报营收增8.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2563835947","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563835947?lang=zh_cn&edition=full","pubTime":"2025-08-31 09:21","pubTimestamp":1756603271,"startTime":"0","endTime":"0","summary":"截至2025年8月29日收盘，奥泰生物报收于72.92元，较上周的75.29元下跌3.15%。本周，奥泰生物8月25日盘中最高价报76.8元。业绩披露要点：奥泰生物2025年中报显示，公司主营收入4.3亿元，同比上升8.41%；归母净利润1.32亿元，同比上升6.57%。公司公告汇总：2025年8月29日，奥泰生物向41名激励对象授予18.80万股限制性股票，授予价格调整为26.2993元/股。股本股东变化截至2025年6月30日，奥泰生物股东户数为5870户，较3月31日增加439户，增幅为8.08%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025083100002818.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688606"],"gpt_icon":0},{"id":"2563880448","title":"奥泰生物（688606）2025年中报简析：营收净利润同比双双增长，三费占比上升明显","url":"https://stock-news.laohu8.com/highlight/detail?id=2563880448","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563880448?lang=zh_cn&edition=full","pubTime":"2025-08-31 06:18","pubTimestamp":1756592337,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期奥泰生物发布2025年中报。截至本报告期末，公司营业总收入4.3亿元，同比上升8.41%，归母净利润1.32亿元，同比上升6.57%。本报告期奥泰生物三费占比上升明显，财务费用、销售费用和管理费用总和占总营收同比增幅达32.3%。然而去年的净利率为34.95%，算上全部成本后，公司产品或服务的附加值极高。持有奥泰生物最多的基金为鹏华弘嘉混合A，目前规模为4.52亿元，最新净值2.937，较上一交易日上涨0.77%，近一年上涨78.05%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025083100001690.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688606"],"gpt_icon":0},{"id":"2563704468","title":"图解奥泰生物中报：第二季度单季净利润同比下降10.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2563704468","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563704468?lang=zh_cn&edition=full","pubTime":"2025-08-29 18:51","pubTimestamp":1756464709,"startTime":"0","endTime":"0","summary":"证券之星消息，奥泰生物2025年中报显示，公司主营收入4.3亿元，同比上升8.41%；归母净利润1.32亿元，同比上升6.57%；扣非净利润1.09亿元，同比上升17.27%；其中2025年第二季度，公司单季度主营收入2.21亿元，同比上升12.61%；单季度归母净利润7079.64万元，同比下降10.49%；单季度扣非净利润5108.74万元，同比下降8.02%；负债率5.93%，投资收益608.43万元，财务费用-1309.24万元，毛利率56.51%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082900036704.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688606"],"gpt_icon":0},{"id":"2558835566","title":"医疗器械行业行业研究：脑机接口行业深度：政策+创新双轮驱动，商业化落地进入快车道","url":"https://stock-news.laohu8.com/highlight/detail?id=2558835566","media":"国金证券","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558835566?lang=zh_cn&edition=full","pubTime":"2025-08-10 12:06","pubTimestamp":1754798792,"startTime":"0","endTime":"0","summary":"投资逻辑国内政策叠加资本双重支持，行业迎来重大发展机遇。近年来国内政策端对脑机接口行业支持力度较高，支持性政策在产品注册、医保支付、行业标准等层面均有体现。1）在产品注册方面，国家药监局将配合相关部门出台基于脑机接口技术的医疗器械产品支持政策，脑机接口相关产品有望通过创新器械绿色通道实现更快注册审批。其中医疗健康领域仍是脑机接口应用最大的细分领域。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025081012063594da7295&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025081012063594da7295&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600587","688273","688426","603014","688067","688677","688271","603976","688389","688139","600807","603309","688236","688151","603387","688026","688575","688580","688606","688613","688755","688301","688029","688161","688212","688016","688314","603205","688410","688351","605369","688013","600055","688217","688050","159883","688068","688338","688317","603880","688085","688108","560260","688656","600645","688298","688393","688468","688277","688358","603658","688576","688617","688581","603987","688198","688607","688075","600529","688253","688366","688767","688114","603222","688193","688289"],"gpt_icon":0},{"id":"2558500614","title":"每周股票复盘：奥泰生物（688606）调整限制性股票授予价格并确定归属名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2558500614","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558500614?lang=zh_cn&edition=full","pubTime":"2025-08-10 04:45","pubTimestamp":1754772311,"startTime":"0","endTime":"0","summary":"关于作废2022年限制性股票激励计划部分限制性股票的公告因3名激励对象离职，公司作废其已获授但尚未归属的限制性股票合计6,177股。关于2022年限制性股票激励计划首次授予第三个归属期及预留授予第二个归属期符合归属条件的公告首次授予第三个归属期拟归属409,472股，预留授予第二个归属期拟归属29,418股，合计438,890股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025081000001046.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688606","BK0239"],"gpt_icon":0},{"id":"2557528689","title":"奥泰生物：44万股限制性股票符合归属条件","url":"https://stock-news.laohu8.com/highlight/detail?id=2557528689","media":"财中社","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557528689?lang=zh_cn&edition=full","pubTime":"2025-08-08 17:12","pubTimestamp":1754644357,"startTime":"0","endTime":"0","summary":"8月8日，奥泰生物（688606）发布公告，公司2022年限制性股票激励计划首次授予第三个归属期及预留授予第二个归属期符合归属条件。本次可归属的限制性股票数量合计为44万股，本次首次授予符合条件的94名激励对象可归属的限制性股票数量合计为41万股，预留授予符合条件的18名激励对象可归属的限制性股票数量合计为3万股。2025年一季度，奥泰生物实现收入2.08亿元，归母净利润6122万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080817355194d76ca5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080817355194d76ca5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688606","BK0239"],"gpt_icon":0},{"id":"2557864522","title":"奥泰生物：8月8日召开董事会会议","url":"https://stock-news.laohu8.com/highlight/detail?id=2557864522","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557864522?lang=zh_cn&edition=full","pubTime":"2025-08-08 17:10","pubTimestamp":1754644235,"startTime":"0","endTime":"0","summary":"每经AI快讯，奥泰生物（SH 688606，收盘价：74.15元）8月8日晚间发布公告称，公司第三届第十四次董事会会议于2025年8月8日在公司会议室以现场与通讯相结合的方式召开。会议审议了《关于<调整2022年限制性股票激励计划授予价格>的议案》等文件。2024年1至12月份，奥泰生物的营业收入构成为：体外诊断行业占比99.51%，其他业务占比0.49%。截至发稿，奥泰生物市值为59亿元。每经头条（nbdtoutiao）——时速21万公里，外星探测器伪装成彗星将“攻击”地球？哈佛知名教授：建议全球建立“宇宙防御系统”！中国专家：并无明显异常（记者 曾健辉）","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808173525973b81a1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808173525973b81a1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688606","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1768335362108,"stockEarnings":[{"period":"1week","weight":0.0188},{"period":"1month","weight":0.0483},{"period":"3month","weight":-0.0178},{"period":"6month","weight":-0.0152},{"period":"1year","weight":0.0876},{"period":"ytd","weight":0.0326}],"compareEarnings":[{"period":"1week","weight":0.0135},{"period":"1month","weight":0.0641},{"period":"3month","weight":0.0579},{"period":"6month","weight":0.1768},{"period":"1year","weight":0.3094},{"period":"ytd","weight":0.0428}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"杭州奥泰生物技术股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"5665人(较上一季度减少1.29%)","perCapita":"13994股","listingDate":"2021-03-25","address":"浙江省杭州市钱塘区经济技术开发区白杨街道银海街550号第3幢第4幢第5幢厂房","registeredCapital":"7928万元","survey":" 杭州奥泰生物技术股份有限公司的主营业务是体外快速诊断试剂的研发、生产和销售。公司的主要产品是传染病类、毒品及药物滥用类、妇女健康类、新冠检测类、肿瘤类、心肌类。报告期内，公司新增授权专利/软件著作权共23项；新增国内外医疗器械产品认证203项。截至报告期末，公司已累计获得专利/软件著作权219项，累计已取得国内外医疗器械备案以及产品注册证书3058项。","listedPrice":133.67},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"奥泰生物(688606)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供奥泰生物(688606)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"奥泰生物,688606,奥泰生物股票,奥泰生物股票老虎,奥泰生物股票老虎国际,奥泰生物行情,奥泰生物股票行情,奥泰生物股价,奥泰生物股市,奥泰生物股票价格,奥泰生物股票交易,奥泰生物股票购买,奥泰生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"奥泰生物(688606)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供奥泰生物(688606)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}